She doesn't want to spend time fighting with her health insurer. After all, she's terminally ill. However, she said she ...

The first study participant was enrolled in July 2024, and since that time, the consortium has recruited over 300 ...

Recent research shows that only 5% to 10% of patients have a family member diagnosed with the disease, and there are only a handful of known genetic mutations. So, what's causing the other 90% of ...

SNUG01 is a first-in-class targeted gene therapy that’s designed to increase the levels of TRIM72, a protein with ...

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing ...

Q4 2024 Earnings Call Transcript March 31, 2025 Brainstorm Cell Therapeutics Inc. reports earnings inline with expectations.

All intellectual and work property derived from DiagnaMed’s research activities in amyotrophic lateral sclerosis (ALS) and its Orphan Drug Designation (ODD) for molecular hydrogen in the treatment of ...

After losing her husband to ALS, Indu Navar used her tech background to create real change. Learn how she built a data-driven ...